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Objective: To describe factors associated with survival in Alzheimer disease (AD) in a multiethnic,
population-based longitudinal study.
Methods: AD cases were identified in the Washington Heights Inwood Columbia Aging Project, a
longitudinal, community-based study of cognitive aging in Northern Manhattan. The sample com-
prised 323 participants whowere initially dementia-free but developed AD during study follow-up
(incident cases). Participants were followed for an average of 4.1 (up to 12.6) years. Possible
factors associated with shorter lifespan were assessed using Cox proportional hazards models
with attained age as the time to event (time from birth to death or last follow-up). In subanalyses,
median postdiagnosis survival durations were estimated using postdiagnosis study follow-up as
the timescale.
Results: The mortality rate was 10.7 per 100 person-years. Mortality rates were higher among
those diagnosed at older ages, and among Hispanics compared to non-Hispanic whites. The me-
dian lifespan of the entire sample was 92.2 years (95% CI: 90.3, 94.1). In a multivariable-
adjusted Cox model, history of diabetes and history of hypertension were independently
associated with a shorter lifespan. No differences in lifespan were seen by race/ethnicity after
multivariable adjustment. The median postdiagnosis survival duration was 3.7 years among non-
Hispanic whites, 4.8 years among African Americans, and 7.6 years among Hispanics.
Conclusion: Factors influencing survival in Alzheimer disease include race/ethnicity and comorbid
diabetes and hypertension. Neurology® 2008;71:1489–1495
GLOSSARY
AD Alzheimer disease; NDI National Death Index; WHICAPWashington Heights Inwood Columbia Aging Project.
Recent estimates of survival in Alzheimer disease (AD) range from 3 to 9 years.1-12 Most of
these studies examined patients with prevalent AD, with survival calculated either from study
entry3,4,7,9,13,14 or from retrospectively estimated dates of disease onset.12 For a summary of
recent population-based studies of mortality in AD, see table 1. Estimating survival time using
prevalent disease cohorts is problematic because of diversity in baseline disease severity. Includ-
ing cases of advanced disease can lead to underestimation of survival. On the other hand,
survival can be overestimated when patients who die rapidly after diagnosis are not recruited
into studies. This has been called “survivor” or “length” bias.12
Prospective, population-based studies that start with dementia-free participants and actively
screen for incident disease provide the most unbiased estimates of mortality and survival dura-
tion, yet few such studies have been undertaken in recent years,1,5,8,10,15 and these have been
limited either by small sample sizes1,5,8,15 or ethnic homogeneity.5,8,10,15 The current report is
from the Washington Heights Inwood Columbia Aging Project (WHICAP), a multiethnic,
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population-based, prospective study of cogni-
tive aging in Northern Manhattan. Herein we
provide ethnicity-specific statistics for 323 in-
cident AD cases, taking age, sex, education,
APOE-4 status, and major medical comor-
bidities into account.
METHODS Subjects. Participants in WHICAP come from
two population-based cohorts of Medicare enrollees. Recruit-
ment for the first cohort began in 1992. The study area was the
14 census tracts in Manhattan between (approximately) 155th
and 181st Streets. Lists of all Medicare or Medicaid recipients in
the study area were obtained from the Health Care Financing
Administration. Potential study subjects were then drawn by sys-
tematic random sampling into one of six strata based on ethnic-
ity (Hispanics, non-Hispanic blacks, non-Hispanic whites) and
age (65–74, 75). Most of the Hispanics living in Northern
Manhattan are of Caribbean descent. A total of 2,125 subjects
were interviewed at baseline. A “refreshment” cohort of 2,183
additional participants was formed in 1999 using generally simi-
lar methods, with several exceptions: new lists of beneficiaries
were obtained but those drawn into the 1992 cohort were ex-
cluded; subjects who reported being diagnosed with dementia in
the course of arranging for the initial evaluation were excluded;
the study area was extended to encompass all of Manhattan
north of 145th Street.
Of participants from the above two cohorts, 458 individuals
developed dementia over the course of the follow-up period (in-
cident cases). Of these, 417 were diagnosed with AD, 323 of
whom had available follow-up data. Of the 94 participants with
AD who lacked follow-up data, 92 had not yet been seen for the
next assessment cycle (recently diagnosed incident cases), leaving
2 lost to follow-up. Those without follow-up data or lost to
follow-up did not vary from the analysis sample in race/ethnic-
ity, gender, APOE- 4 status, and most medical comorbidities
(hypertension, stroke, or malignancy), but were more likely to
have a history of heart disease (p  0.03), and were older at AD
diagnosis (p  0.003).
The study was reviewed and approved by the Columbia Uni-
versity institutional review board, and written informed consent
was obtained from all subjects.
Assessment of incident AD. Physician-administered physi-
cal and neurologic examinations, along with a standardized neu-
ropsychological battery,16 were used to diagnose AD. All
assessments were administered at baseline and at subsequent
follow-up visits, which occurred at approximately 18-month in-
tervals. Evaluations were conducted in either English or Spanish,
based on participant preference. All available ancillary informa-
Table 1 Comparison of previous community-based studies of survival in participants diagnosed with AD:
1990–present
Study
(ref. no.) Sample type No. AD cases Case type Median survival time
41 Community-based cohort:
East Boston, MA
134 Prevalent Not reported
13 Community-based cohort:
Netherlands
167 Prevalent Not reported
25 Community-based cohort:
England
222 Prevalent Not reported
3 Community survey: Finland 218 Prevalent 5 y
42 Population-based cohort:
Seattle, WA
327 Prevalent Not reported
7 Community-based cohort:
Canada
739 Prevalent Not reported
12 Population-based cohort:
Canada





62 Incident Not reported
2 Population-based medical
record review: Rochester, MN










101 Incident 3.1 y
14 Population-based cohort:
France
189 Incident 4.5 y
8 Volunteer community cohort:
Baltimore, MD
108 Incident 75 y: 6.0 y; 75–84:
5 y; 85: 3.5 y
10 Community-based cohort:
rural Pennsylvania
330 Incident (with estimated onset
dates)
5.9 y from onset of
symptoms; 3.8 y for
onset after 85 y
WHICAP Population-based cohort:
Northern Manhattan, NY
323 Incident Whites: 3.7 y; African
Americans: 4.8 y;
Hispanics: 7.6 y
AD Alzheimer disease; WHICAPWashington Heights Inwood Columbia Aging Project.
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tion, including medical charts and imaging studies, was consid-
ered in the evaluations.
Consensus diagnosis of dementia/no dementia was made at
diagnostic conferences attended by neurologists and neuropsy-
chologists, using results from the neuropsychological battery as
well as evidence of social or occupational function deficits. The
type of dementia was subsequently determined based on Diag-
nostic and Statistical Manual of Mental disorders, Revised Third
Edition criteria. Diagnosis of probable or possible AD was made
based on criteria suggested by the National Institute of Neuro-
logical and Communicative Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association. Only participants
identified as having possible or probable AD were included in
our analysis.
Assessment of mortality status and covariates. Mortality
was tracked through follow-up interviews every 18 months and
submission of identifying information to the National Death
Index. Demographic information (age, sex, ethnicity, years of
education) and major medical comorbidities (heart disease, hy-
pertension, stroke, diabetes, and malignancy) up to dementia
incidence were considered in analyses. Stroke was defined ac-
cording to the World Health Organization criteria.17 Medical
condition diagnoses were assessed based on questioning each
participant (or a proxy if necessary) about the presence of
physician-diagnosed conditions. Diagnostic assessments were
supplemented by results of a neurologic examination and review
of medical records. Diabetes and hypertension were defined as a
reported history of or documented treatment of either disorder
at any time up to AD diagnosis. Heart disease was defined as a
history of myocardial infarction, congestive heart failure, or an-
gina pectoris at any time prior to or including the AD diagnosis
visit.
Ethnicity was based on 1990 US Census designations. Edu-
cation was dichotomized based on a cutpoint of 12 years (high
school education). The Clinical Dementia Rating18 was used to
assess the severity of dementia and at the incidence visit.
Statistical methods. Baseline characteristics by survival status
were compared using 2 or t tests. Case-fatality rates were strati-
fied by age group (75, 75–84, 85), sex, and race/ethnic
group. Age group–specific (85, 85) case-fatality rates were
then calculated within race strata. Rates were calculated by divid-
ing the number of deceased participants by person-years of study
follow-up, then multiplying by 100. Case-fatality rates differ
from mortality rates as they are calculated using data only from
cases, rather than using data from cases and non-cases from the
same cohort.
Survival analyses used lifespan (attained age) as the time to
event scale.19,20 Attained age was measured as birth date to 1) date
of death or 2) date of last follow-up. Death dates were deter-
mined via study follow-up and by an audit of the National
Death Index (NDI) through December 31, 2002. If we learned
of cases who died following this audit date, such cases were also
included as deaths. For cases defined as living, last follow-up was
defined as last clinical assessment or NDI audit date, whichever
came last.
Kaplan-Meier curves and log-rank statistics were used to de-
termine median lifespans and to compare cumulative survival
between groups.21 Cox proportional hazards regression models
were used to assess the effects of baseline characteristics on sur-
vival.22 Cox models were stratified on median age at AD diagno-
sis. The unadjusted effects of baseline characteristics (sex, race/
ethnicity, education, heart disease, stroke, hypertension,
diabetes) on survival were assessed in separate bivariate Cox
models. Multivariable Cox models were used to evaluate the si-
multaneous effects of the above mentioned baseline characteris-
tics, as well as study follow-up time, on survival.
Several supplementary analyses were completed. In a sub-
sample of 288 participants with available genotyping data, we
explored the effect of APOE-4 on survival. We also examined
survival separately in a subsample of patients with AD with
concomitant stroke. Additionally, for comparison to previous
studies, we calculated postdiagnosis survival duration. In
Kaplan-Meier models that used postdiagnosis follow-up as the
timescale, we estimated median postdiagnosis survival by age at
diagnosis (75, 75–84, 85 years), sex, and ethnicity.
Finally, we compared our postdiagnosis survival duration to
expected survival in the US population by 5-year age groups
based on US life table estimates that included Hispanics.23
Analysis of Martingale residuals was used to verify the valid-
ity of the proportional hazards assumption.24 All analyses were
done using SPSS version 12.0.
RESULTS Characteristics of study population. The
mean age of the sample at baseline was 87.0 years
(range 67 to 100 years). The sample was 70%
women, 55% Hispanic (mainly of Caribbean ances-
try) and 33% African American.
Differences by mortality status. Those who died were
more likely to be white (non-Hispanic) or African
American. Additionally, those who died tended to be
more highly educated (table 2).
Differences by ethnicity. There were no differences in
age at study baseline or at diagnosis by race/ethnicity.
Whites had the most education (mean 10.5 years)
followed by blacks (8.5 years) and Hispanics (5.1
years) (p  0.0001). There were no race/ethnic dif-
ferences in APOE-4 status, sex, or history of stroke,
diabetes, hypertension, or malignancy (data not
shown).
Case-fatality rates. Person-year-adjusted case-fatality
rates are presented in table 3. No sex differential in
case-fatality was found. The case-fatality rate among
non-Hispanic whites was more than twice as high as
the rate among Hispanics. Case-fatality rates for the
oldest age group (85 years or older) were more than
double that of the youngest group (less than 75
years).
Influence of baseline characteristics on survival. In
Cox models using lifespan as the time scale, only hyper-
tension and diabetes were independently associated
with shorter lifespan (table 4). In supplementary analy-
ses that used postdiagnosis follow-up as the time scale,
median survival after diagnosis was 6.0 years (95% CI
5.0, 7.1). For those younger than age 75 at diagnosis,
median postdiagnosis survival was 9.9 years (95% CI
6.8, 13.0); for those 75–84 at diagnosis, 6.9 years (95%
CI 5.4, 8.5); and for those 85 at diagnosis, 4.4 years
(95% CI 3.5, 5.3) (log-rank statistic  20.1; p 
0.0001). Postdiagnosis survival was shortest among
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non-Hispanic whites (3.7 years; 95% CI 1.5, 5.9), fol-
lowed by African Americans (4.8 years; 95% CI 4.0,
5.7) and Hispanics (7.6 years; 95% CI 6.4, 8.7) (log-
rank statistic 20.8, p 0.0001) (figure). No sex dif-
ferences were found.
Lifespan among those with AD with concomitant
vascular disease did not differ from those with “pure”
AD (log-rank statistic  1.30, p  0.24). Survival
among individuals with incident AD was shorter
than what would be expected based on US census-
based life table estimates.23 The median survival of
those with incident AD was 3 years less than the
overall population for those diagnosed at 70–75
years old, and 1–2 years less than the overall popula-
tion for those diagnosed at older ages.
DISCUSSION This study provides survival statistics
for a multiethnic sample of incident AD cases. Patients
with AD in this study, whowere on average 83 years old
at diagnosis, had a median lifespan of 92.2 years. Al-
though this longevity may seem remarkable, it is still
1–3 years less than the expected conditional lifespan
based on population-wide life table estimates, depend-
ing on age at diagnosis. Factors independently associ-
ated with shorter lifespan among patients with AD
included history of hypertension and diabetes.
An advantage to this study is that we included
only participants with incident AD. Previous investi-
gators reported that survival may be overestimated in









Age at diagnosis, mean  SD 83.0 6.6 82.0 6.1 84.1 7.1 0.01
Sex, n (%)
Female 225 (69.7) 128 (69.9) 97 (69.3) 0.90
Male 98 (30.3) 55 (30.1) 43 (30.7)
Ethnicity, n (%)
White 35 (10.8) 17 (9.3) 18 (12.9) 0.04
African American 106 (32.8) 50 (27.3) 56 (40.0)
Hispanic 179 (55.4) 114 (62.3) 65 (46.4)
Other 3 (0.9) 2 (1.1) 1 (0.9)
Education, y, mean  SD 6.9 4.6 6.1 4.5 7.8 4.6 0.001
Study cohort, n (%)
92 250 (77.4) 119 (65.0) 131 (93.6) 0.001
99 73 (22.6) 64 (35.0) 9 (6.4)
Follow-up time, y, mean  SD 4.05 2.86 4.3 6.5 3.7 2.6 0.09
Heart disease, n (%) 116 (35.9) 67 (36.6) 49 (35.0) 0.77
Hypertension,* n (%) 248 (91.5) 142 (89.9) 106 (93.8) 0.25
Stroke, n (%) 83 (25.7) 44 (24.0) 39 (27.9) 0.44
Diabetes, n (%) 99 (30.7) 49 (26.8) 50 (35.7) 0.08
Malignancy,* n (%) 33 (13.4) 13 (11.1) 20 (15.4) 0.32
Presence of at least one APOE-4 allele* 91 (31.6) 52 (31.9) 39 (31.2) 0.90
Clinical Dementia Rating at diagnosis, mean  SD 2.2 2.5 2.4 2.5 1.9 2.4 0.06
Reported percentages are based on the subset with available data: for APOE-4 n  288, for hypertension n  271, for
malignancy n 247.
AD Alzheimer disease.








Overall 140 1,308.5 10.7 —
Race/ethnicity
Non-Hispanic white 18 89.2 20.2 Referent group
African American 56 400.8 13.9 0.14
Hispanic 65 802.1 8.1 0.001
Sex
Male 43 370.5 11.6 0.51
Female 97 938.0 9.9
Age at diagnosis, y
<75 15 214.6 7.0 Referent group
75–84 66 727.7 9.1 0.34
85 59 366.2 16.1 0.001
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studies of prevalent disease. This could occur when
cases of rapidly progressing disease are not identified
before death and are thus omitted from studies.12
However, there is also the competing risk that sur-
vival may be underestimated, since individuals are
captured later in the disease course, instead of at the
point of disease onset.
As in other recent studies of incident AD,8,12,14 we
found that older age at AD diagnosis was associated
with significantly shorter postdiagnosis survival.
Those in the youngest age group at diagnosis (75
years) survived more than twice as long as those in
the oldest group (85), probably because older pa-
tients are more likely to die of other causes. In con-
trast with most3-5,9,25,26 but not all8 recent studies, we
did not find a survival advantage among women.
Our sample was predominately Hispanic. According
to US life table estimates,23 in the overall non-
Hispanic white population, life expectancy is mark-
edly higher in women compared to men among
those aged 80 and older. In contrast, there are negli-
gible differences by sex in this age group among His-
panics. Thus our finding of a lack of a sex differential
(and perhaps previous studies’ findings of a female
advantage) may reflect sex-related life expectancy in
the background populations studied.
The mortality rate was highest among non-
Hispanic whites—approximately twice as high as the
rate among Hispanics. The mortality rate among Af-
rican Americans was lower than that of non-Hispanic
whites and higher than that of Hispanics.
Our finding of a 3.7-year postdiagnosis survival
among non-Hispanic whites is consistent with previous
studies of incident AD with predominantly Caucasian
samples. The Baltimore Longitudinal Study of Aging
found that the median survival duration among men
was 3.8 years and 4.4 years among women.8 The
French PAQUID study reported a median survival
duration of 3.7 years for men and 5.2 for women.14
The Canadian Study of Health and Aging found me-
dian survival of 2.8 years among those with prevalent
AD, after adjusting for length bias.12
We found markedly longer postdiagnosis sur-
vival among Hispanic participants, yet no race/
ethnic differences in lifespan. This might be
explained by assessment bias brought about by the
lower educational attainment among Hispanics
compared to the other ethnic groups. Those with
less education often perform slightly worse on
standardized cognitive tests despite comparable
disease pathology. Thus, the Hispanics in this
study might have been identified as having AD
earlier than those in other ethnic groups; nonethe-
less, the mean age at diagnosis did not vary by
ethnicity. We considered the possibility that eth-
nic differences in medical comorbidity might ex-
plain differences in survival—yet the prevalence of
diabetes and hypertension was higher, not lower,
Figure Kaplan-Meier curves depicting
postdiagnosis survival by
race/ethnic group





Overall 92.2 (90.3, 94.1)
Ethnicity
Hispanic 93.7 (91.2, 96.3) 1.0†
White 91.1 (86.4, 95.8) 0.69 (0.35, 1.36)
Black 91.4 (89.0, 93.8) 0.95 (0.63, 1.44)
Sex
Female 92.1 (89.3, 96.9) 1.0†
Male 92.2 (90.1, 94.3) 1.12 (0.73, 1.72)
Hypertension
No 105.5 (83.4, 127.5) 1.0†
Yes 92.1 (90.2, 94.0) 2.57 (1.04, 6.37)‡
Stroke history
No 92.5 (90.3, 94.6) 1.0†
Yes 91.4 (88.4, 94.4) 1.16 (0.77, 1.74)
One or more APOE-4 alleles
No 92.5 (89.7, 95.2) 1.0†
Yes 92.1 (89.8, 94.4) 1.27 (0.81, 1.99)
Diabetes
No 94.3 (92.1, 96.6) 1.0†
Yes 88.4 (86.7, 90.1) 1.99 (1.32, 2.99)§
*Adjusted for ethnicity, sex, education (high school or above), history of heart disease, hy-
pertension at baseline visit, history of stroke, history of diabetes, study cohort, and
follow-up time. Models were stratified on median age at dementia onset. History of heart
disease, history of malignancy, and education were not predictive of shorter survival in any
of the models. APOE-4 data were available for 89% of the sample.
†This group served as the reference category.
‡p 0.05, §p 0.001.
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among Hispanics than in the other ethnicities.
There is a growing literature supporting a survival
advantage among Hispanics in the United States
compared to other race/ethnic groups, which may
be explained by ethnic differences in health-
related behaviors, family networks, and social sup-
port.27,28 Thus, our findings among Hispanics may
reflect comparatively longer survival among all US
Hispanics. Our findings are consistent with a re-
cent large study of patients enrolled in US Alzhei-
mer’s Disease Centers, which found that survival
(measured from first ADC visit) was longer among
Hispanic and African American patients with AD
compared to non-Hispanic whites, with Hispanics
surviving the longest.29
Like others,9 we found that diabetes was indepen-
dently associated with shorter survival. In contrast to
previous findings9 we additionally found that hyper-
tension was associated with shorter survival. In con-
trast to most previous studies,3,9,25 we found no link
between survival duration and a history of heart dis-
ease or malignancy among patients with AD.
We did not find a differential effect of the pres-
ence of at least one APOE-4 allele on survival. The
APOE-4 genotype has been associated with earlier
disease onset,30 and some31,32 but not all33,34 studies
have demonstrated more rapid disease progression
among 4 carriers. Indeed, in a separate analysis of
this cohort, we demonstrated faster cognitive decline
among incident cases who were 4 carriers.35 Our
failure to demonstrate an 4-associated difference in
survival may reflect a differential effect of 4 in the
earlier stages of disease that is eclipsed by other fac-
tors (medical, social, or disease-related factors) later
in the disease course.
Results of previous studies that considered the ef-
fect of APOE-4 on survival in AD have been con-
flicting. One small study found shorter survival in
male, but not female, 4-carriers.36 We found no dif-
ferential 4 effect by sex. Others found longer sur-
vival among 4 carriers,37,38 and still others found no
association.39,40
Several issues should be considered in inter-
preting our findings. First, our follow-up visits
were roughly separated by 1.5 years, possibly af-
fecting the precision of our incidence dates. Sec-
ond, 96 participants with AD had not yet been
seen for the next assessment cycle. These individu-
als may be at higher risk of dying and may have
skewed our results toward longer survival time.
Third, our sample differs from the general US
population in that it consists of 55% Caribbean
Hispanics and is mostly women (70%). Also, sub-
jects under age 65 were not assessed, thus we likely
excluded some individuals who developed AD at a rela-
tively young age and died prior to study entry. These
factors may limit the generalizability of our findings.
Finally, we were unable to report particular causes of
death among patients with AD since this information
was not available for most participants.
Despite these possible limitations, confidence in our
findings is strengthened by the fact that the WHICAP
study is by design an investigation of cognitive aging.
All participants were seen for frequent follow-up assess-
ments by neurologists with experience in dementia. In
lieu of cognitive screening instruments used in some
studies, we administered a comprehensive battery of
neuropsychological tests at each follow-up assessment,
and case status was determined after careful consider-
ation in consensus conferences attended by study neu-
rologists and neuropsychologists. The fact that our
sample is mainly population-based reduces biases asso-
ciated with the use of convenience samples (disease reg-
istries, hospital- or clinic-based samples) that may not
accurately reflect the course of the disease in the general
population.
Most recent community-based studies have
been limited by the study of only prevalent
cases.3,7,12,13,25,41,42 Of the studies that actively
screened dementia-free individuals for incident
AD, most were limited by small samples1,5,8,14,15
(table 1). Our large sample of persons with inci-
dent AD was drawn from a representative sample
of a multiethnic community, thus our findings ex-
tend those of other recent community-based stud-
ies that included mostly white participants.
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